Advocacy for alternatives to animal testing in clinical research is pushing the industry away from animal-based endotoxin ...

The European Union (EU) is actively courting biotech for economic growth and has launched several initiatives to attract ...

Experts at Faegre Drinker offer life sciences business planning and risk mitigation strategies to consider in response to ...

After decades of racing to the bottom on pricing, a revolution is coming to the U.S. generics market, writes Yaral Pharma CEO ...

Modern drug development approaches that integrate functional plans with larger business goals are needed for success in early ...

On this week's Business of Biotech episode, Dr. Srinivas Rao, co-founder and CEO at atai Life Sciences, explains how his engineering background led him to the development of psychedelic compounds for ...

It was the summer of 2007 when Chris Anzalone, Ph.D., got a call from Arrowhead Research Company. At the time, Anzalone was working as CEO of the Bennet Group, a private equity firm in Washington, D.C ...

In the 1980s, Lisa Conte was a biopharmaceutical venture capitalist. But she also was an aspiring entrepreneur, having a little business on the side called Wild Woods, which imported wood and ...

The number of psychedelic drug developers reaching Phase 2 and Phase 3 clinical trials is growing, in recognition of the level of unmet need in many mental health disorders and other conditions. Those ...

For people living with schizophrenia, the current drug treatment landscape is filled with cracks, crevices, and canyons that prevent a majority of patients from reaching anything close to a normal ...

When Tryon Medical Partners left a large medical system in 2018 to once again become an independent group, clinical research was part of our stated mission. Our group of over 100 physicians now has ...

As anxiety disorders become more common and stress from the diverse impacts of the COVID-19 pandemic threaten the mental/emotional well-being of Americans everywhere, it is clear that the current ...